+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Oropharyngeal Candidiasis Drug"

From
  • 1 Results (Page 1 of 1)
Loading Indicator

Oropharyngeal Candidiasis (OPC) is a fungal infection of the mouth and throat caused by the yeast Candida albicans. It is the most common form of candidiasis and is often referred to as thrush. OPC is a common opportunistic infection in immunocompromised individuals, such as those with HIV/AIDS, and is also seen in patients undergoing chemotherapy or taking antibiotics. Treatment of OPC typically involves antifungal medications, such as fluconazole, itraconazole, and amphotericin B. The OPC drug market is a subset of the larger infectious diseases drug market. It is a highly competitive market, with a number of generic and branded drugs available. The market is driven by the increasing prevalence of OPC, as well as the rising demand for antifungal medications. Some of the major companies in the OPC drug market include Pfizer, Merck, GlaxoSmithKline, Novartis, and AstraZeneca. Show Less Read more